L01XX32 • bortezomib • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Bortezomibum is a medication used for the treatment of multiple myeloma and mantle cell lymphoma. It is a proteasome inhibitor that interferes with essential cellular processes in cancer cells, leading to their death.
The medication is administered via subcutaneous or intravenous injection, usually in treatment cycles, as directed by a doctor. The dosage and duration of treatment are adjusted based on the patient's condition and response to therapy.
Common side effects include fatigue, nausea, diarrhea, peripheral neuropathy, and decreased blood cell counts. In rare cases, more severe adverse effects such as heart failure or pulmonary toxicity may occur.
Bortezomibum is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
Substance: bortezomib
Date of last drug list: 19-03-2019
Commercial code: W65321001
Concentration: 3.5mg
Pharmaceutical form: powder for injection
Quantity: 1
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: PHARMIDEA SIA - LITUANIA
Holder: CHEM AFFAIRS ''DEUTSCHLAND''GMBH - GERMANIA
Number: 10807/2018/01
Shelf life: 3 years;after reconstitution-it is used immediately